Barely Significant
← all excerpts

Population Exposure-Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma.

Target Oncol · 2025 · PMC12454538 · PMID 40826257

Europe PMCDOI
1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

a significant trendp -value < 0.0001actually significant
The KM curves indicated there was a separation of survival probabilities for PFS among the C ave,day28 , C ave,day42 , C ave,day56 , and C ave,day70 quartiles, and there was a significant trend of survival benefit of PFS for the higher exposure quartile (Q4 > Q3 > Q2 > Q1, p -value < 0.0001).

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.